
Benedikt Schrage

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1936335/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Concomitant implantation of Impella [®] on top of venoâ€arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. European Journal of Heart Failure, 2017, 19, 404-412.	2.9	402
2	Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. Circulation, 2019, 139, 1249-1258.	1.6	353
3	Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation. Circulation, 2020, 142, 2095-2106.	1.6	269
4	Application of the SCAI classification in a cohort of patients with cardiogenic shock. Catheterization and Cardiovascular Interventions, 2020, 96, E213-E219.	0.7	122
5	Unloading of the Left Ventricle During Venoarterial Extracorporeal Membrane Oxygenation Therapy in CardiogenicÂShock. JACC: Heart Failure, 2018, 6, 1035-1043.	1.9	105
6	Venoarterial Extracorporeal Membrane Oxygenation for Cardiopulmonary Support. Circulation, 2018, 138, 2298-2300.	1.6	92
7	Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure. Circulation, 2019, 140, 1530-1539.	1.6	78
8	Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock. ESC Heart Failure, 2021, 8, 1295-1303.	1.4	69
9	Hemodynamic Effects of Mechanical Circulatory Support Devices in Ventricular Septal Defect. Circulation: Heart Failure, 2019, 12, e005981.	1.6	62
10	Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: De-escalate and ambulate. Journal of Critical Care, 2020, 57, 259-263.	1.0	47
11	Influence of age and shock severity on short-term survival in patients with cardiogenic shock. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 604-612.	0.4	45
12	Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the <scp>S</scp> wedish <scp>H</scp> eart <scp>F</scp> ailure <scp>R</scp> egistry. European Journal of Heart Failure, 2021, 23, 1844-1854.	2.9	42
13	Adherence to Mediterranean diet, high-sensitive C-reactive protein, and severity of coronary artery disease: Contemporary data from the INTERCATH cohort. Atherosclerosis, 2018, 275, 256-261.	0.4	36
14	Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock. Journal of the American College of Cardiology, 2022, 79, 1949-1962.	1.2	36
15	Neuron-specific-enolase as a predictor of the neurologic outcome after cardiopulmonary resuscitation in patients on ECMO. Resuscitation, 2019, 136, 14-20.	1.3	33
16	Use of <scp>sodium–glucose</scp> coâ€ŧransporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2021, 23, 1012-1022.	2.9	33
17	Procedural volume and outcomes in patients undergoing VA-ECMO support. Critical Care, 2020, 24, 291.	2.5	32
18	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. International Journal of Cardiology, 2020, 313, 76-82.	0.8	30

#	Article	IF	CITATIONS
19	Percutaneous Transvalvular Microaxial Flow Pump Support in Cardiology. Circulation, 2022, 145, 1254-1284.	1.6	29
20	Patient Characteristics, Treatment and Outcome in Non-Ischemic vs. Ischemic Cardiogenic Shock. Journal of Clinical Medicine, 2020, 9, 931.	1.0	28
21	Impella 5.0 therapy as a bridge-to-decision option for patients on extracorporeal life support with unclear neurological outcomes. European Journal of Cardio-thoracic Surgery, 2019, 56, 1031-1036.	0.6	27
22	Association between betaâ€blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity scoreâ€matched analysis from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2020, 22, 103-112.	2.9	27
23	Risk prediction of in-hospital mortality in patients with venoarterial extracorporeal membrane oxygenation for cardiopulmonary support: The ECMO-ACCEPTS score. Journal of Critical Care, 2020, 56, 100-105.	1.0	27
24	Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure. Heart, 2021, 107, 229-236.	1.2	26
25	Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause–Âthe Cardiogenic Shock Score. European Journal of Heart Failure, 2022, 24, 657-667.	2.9	26
26	Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials. European Journal of Heart Failure, 2021, 23, 1942-1951.	2.9	25
27	Patient profile and outcomes associated with followâ€up in specialty vs. primary care in heart failure. ESC Heart Failure, 2022, 9, 822-833.	1.4	23
28	Alcohol intake and total mortality in 142 960 individuals from the MORGAM Project: a populationâ€based study. Addiction, 2022, 117, 312-325.	1.7	22
29	Iron deficiency is a common disorder in general population and independently predicts all-cause mortality: results from the Gutenberg Health Study. Clinical Research in Cardiology, 2020, 109, 1352-1357.	1.5	21
30	Macrophage Migration Inhibitory Factor (MIF) Expression Increases during Myocardial Infarction and Supports Pro-Inflammatory Signaling in Cardiac Fibroblasts. Biomolecules, 2019, 9, 38.	1.8	20
31	Mechanical circulatory support devices in cardiogenic shock and acute heart failure: current evidence. Current Opinion in Critical Care, 2019, 25, 391-396.	1.6	19
32	Sex differences in patients with cardiogenic shock. ESC Heart Failure, 2021, 8, 1775-1783.	1.4	17
33	Association Between the Acidemia, Lactic Acidosis, and Shock Severity With Outcomes in Patients With Cardiogenic Shock. Journal of the American Heart Association, 2022, 11, e024932.	1.6	15
34	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. Journal of Cardiac Failure, 2021, 27, 888-895.	0.7	14
35	Effective treatment with a new protocol using tissue-type plasminogen activator thrombolysis for pump thrombosis with the HVAD device. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 766-770.	0.4	13
36	Nonâ€insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. ESC Heart Failure, 2020, 7, 3438-3451.	1.4	13

#	Article	IF	CITATIONS
37	Comparison of Cardiovascular Risk Factors in European Population Cohorts for Predicting Atrial Fibrillation and Heart Failure, Their Subsequent Onset, and Death. Journal of the American Heart Association, 2020, 9, e015218.	1.6	13
38	Switching to Impella 5.0 decreases need for transfusion in patients undergoing temporary mechanical circulatory support. Journal of Critical Care, 2020, 57, 253-258.	1.0	13
39	Association of iron deficiency with incident cardiovascular diseases and mortality in the general population. ESC Heart Failure, 2021, 8, 4584-4592.	1.4	13
40	Impact of therapeutic hypothermia on bleeding events in adult patients treated with extracorporeal life support peri-cardiac arrest. Journal of Critical Care, 2021, 62, 12-18.	1.0	12
41	Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study. Clinical Therapeutics, 2017, 39, 2311-2320.e2.	1.1	10
42	Response by Schrage and Westermann to Letters Regarding Article, "Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study― Circulation, 2021, 143, e1024.	1.6	10
43	Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. Europace, 2022, 24, 48-57.	0.7	10
44	Heart failure in the general population and impact of the 2021 European Society of Cardiology Heart Failure Guidelines. ESC Heart Failure, 2022, 9, 2157-2169.	1.4	10
45	Predictors of primary prevention implantable cardioverterâ€defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and allâ€cause mortality. European Journal of Heart Failure, 2022, 24, 1212-1222.	2.9	10
46	Sealing of Coronary Perforations With a Second-Generation Covered Stent Graft - Results From the PAST-PERF Registry. Cardiovascular Revascularization Medicine, 2021, 25, 20-26.	0.3	9
47	Non-immune risk predictors of cardiac allograft vasculopathy: Results from the U.S. organ procurement and transplantation network. International Journal of Cardiology, 2021, 331, 57-62.	0.8	9
48	Clinical characteristics and outcomes of patients with adult congenital heart disease listed for heart and heart‒lung transplantation in the Eurotransplant region. Journal of Heart and Lung Transplantation, 2020, 39, 1238-1249.	0.3	8
49	Cytokine-Mediated Alterations of Human Cardiac Fibroblast's Secretome. International Journal of Molecular Sciences, 2021, 22, 12262.	1.8	8
50	Distinct Hemodynamic Changes After Interventional Mitral Valve Edgeâ€toâ€Edge Repair in Different Phenotypes of Heart Failure: An Integrated Hemodynamic Analysis. Journal of the American Heart Association, 2018, 7, .	1.6	7
51	Heart Failure in Patients Undergoing Elective and Emergency Noncardiac Surgery: Still a Poorly Addressed Risk Factor. Journal of Cardiac Failure, 2020, 26, 1034-1042.	0.7	7
52	Response by Schrage et al to Letter Regarding Article, "Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Matched-Pair IABP-SHOCK II Trial 30-Day Mortality Analysis― Circulation, 2019, 140, e559-e560.	1.6	5
53	Extracorporeal membrane oxygenation. Deutsches Ärzteblatt International, 2022, , .	0.6	5
54	Right Ventricular Index for Risk Stratification of Patients with Pulmonary Arterial Hypertension. Respiration, 2018, 96, 249-258.	1.2	4

#	Article	IF	CITATIONS
55	Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes—Why Is It Not Used in Clinical Practice?. Thrombosis and Haemostasis, 2018, 118, 1528-1534.	1.8	4
56	Mitral stenosis and atrial fibrillation. Heart, 2020, 106, 713-713.	1.2	4
57	Study design and rationale of the pAtients pResenTing with cOngenital heaRt dIseAse Register (ARTORIAâ€R). ESC Heart Failure, 2021, 8, 5542-5550.	1.4	4
58	Gender differences in characteristics and outcomes in heart failure patients referred for endâ€stage treatment. ESC Heart Failure, 2021, , .	1.4	4
59	Differences in the Treatment of Acute Coronary Syndrome in the Pre-COVID and COVID Era: An Analysis from Two German High-Volume Centers. Journal of Cardiovascular Development and Disease, 2021, 8, 145.	0.8	4
60	Intracranial haemorrhage in adult patients on venoarterial extracorporeal membrane oxygenation. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 303-311.	0.4	4
61	Diastolic dysfunction in individuals with and without heart failure with preserved ejection fraction. Clinical Research in Cardiology, 2022, 111, 416-427.	1.5	3
62	Regional differences in presentation characteristics, use of treatments and outcome of patients with cardiogenic shock: Results from multicenter, international registry. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2021, 165, 291-297.	0.2	3
63	Establishing a robotic-assisted PCI program: experiences at a large tertiary referral center. Heart and Vessels, 2022, 37, 1669-1678.	0.5	3
64	Reply. JACC: Heart Failure, 2019, 7, 364-365.	1.9	2
65	Response by Schrage et al to Letter Regarding Article, "Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry― Circulation, 2020, 141, e648-e649.	1.6	1
66	Seasonal trends of incidence and outcomes of cardiogenic shock : findings from a large, nationwide inpatients sample with 441,696 cases. Critical Care, 2021, 25, 325.	2.5	1
67	Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT‧HOCK Substudy. Journal of the American Heart Association, 2021, 10, e021150.	1.6	1
68	Radiation exposure during the implantation of bioabsorbable vascular scaffolds versus drug-eluting stents in non-complex coronary lesions: a matched-cohort study. Minerva Cardiology and Angiology, 2016, 65, 1-7.	0.4	1
69	Percutaneous coronary intervention for ostial and bifurcation lesions using the Szabo technique: a single center experience. Minerva Cardiology and Angiology, 2017, 65, 331-335.	0.4	1
70	Deâ€escalation of support with venoâ€arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock: reply. European Journal of Heart Failure, 2018, 20, 622-623.	2.9	0
71	Severe ischaemic cardiogenic shock with cardiac arrest and prolonged asystole: a case report. European Heart Journal - Case Reports, 2018, 2, yty088.	0.3	0
72	Septic perimyocarditis due to a rightâ€sided infective endocarditis of atypical morphology in a 33â€yearâ€old woman. Clinical Case Reports (discontinued), 2020, 8, 1486-1488.	0.2	0

#	Article	IF	CITATIONS
73	Detailed interpretation of ECMO-ACCEPTS score. Journal of Critical Care, 2020, 60, 327.	1.0	Ο
74	Importance of swift event adjudication of endpoints for adequate reporting to data and safety monitoring boards in clinical trials—lessons from CULPRIT-SHOCK. Trials, 2021, 22, 197.	0.7	0
75	Extracorporeal Membrane Oxygenation Evolution: LV Unloading Strategies. JTCVS Open, 2021, , .	0.2	Ο
76	OUP accepted manuscript. European Heart Journal: Acute Cardiovascular Care, 2022, , .	0.4	0
77	Enough iron in transcatheter aortic valve implantation already. European Journal of Heart Failure, 2022, 24, 1280-1281.	2.9	0